Closely following a data leak on Oct. 22, Merck officially announced key data points from the phase 3 Interpath-001 study of individualized neoantigen therapy intismeran in melanoma, ahead of an expected Oct. 24 presentation. Moderna shares fell 18% and Merck shares fell 2% on Oct. 22.
The stellar efficacy and safety profile of Moderna's covid vaccine offered rapid validation of the firm's mRNA technology.
Moderna's Alexion partnership was terminated in 2017 after failure to find a safe but effective dose for the lead program, which could foreshadow difficulty finding a therapeutic window beyond low-dose vaccine programs.
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 9.85 |
Price/Book Value | 11.81 | 1.09 | 2.01 |
Price/Sales | 35.63 | 7.07 | 2.70 |
Price/Cash Flow | — | — | 11.17 |
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Quick Ratio | 2.08 | 7.71 | 0.85 |
Current Ratio | 2.29 | 7.85 | 1.27 |
Interest Coverage | −79.21 | — | 2.36 |
|
Metric
|
MRNA
|
BNTX
|
PFE
|
|---|---|---|---|
Return on Assets (Normalized) | −23.64% | −5.73% | 8.46% |
Return on Equity (Normalized) | −33.54% | −6.58% | 19.70% |
Return on Invested Capital (Normalized) | −31.72% | −6.97% | 12.66% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|d^?qFTs | LOCK|@G#^W | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^>^B^! | LOCK|Tp^#g | $83B | |||
| argenx SE ADR
ARGX
| LOCK|TXWf@^D | LOCK|$C | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|mm&$@Jl | LOCK|%W | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<?&sMQx | LOCK|%Znc | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|?PjN?>zx | LOCK|YZXLg | $28B | |||
| Incyte Corp
INCY
| LOCK|&p%#dJ | LOCK|!L? | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|CtD>%Dv | LOCK|f> | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|wNlg>Q^ | LOCK|@mR | $14B |
United States